# Cardinal Health, Inc. (CAH) Stock Analysis: Evaluating a Healthcare Giant with a 9.29% Potential Upside

- Link: https://www.directorstalkinterviews.com/cardinal-health-inc-cah-stock-analysis-evaluating-a-healthcare-giant-with-a-9-29-potential-upside/4121230530
- Published: 2025-12-15T11:37:12+00:00
- Author: Madison Wilson

Cardinal Health, Inc. (NYSE: CAH), a prominent player in the healthcare sector, 
is a powerhouse in the medical distribution industry with a significant market cap
of $47.09 billion. Headquartered in Dublin, Ohio, this company has positioned itself
as a critical component of the healthcare supply chain, serving a wide array of 
healthcare providers with both pharmaceutical and medical products.

Cardinal Health’s current stock price stands at $198.18, exhibiting a negligible
change of -0.14 USD, reflecting a stable market position. Over the past year, its
stock has navigated a broad range, from a low of $115.82 to a high of $213.73, indicating
a significant growth trajectory. Notably, the company’s forward price-to-earnings(
P/E) ratio is pegged at 17.88, suggesting that investors are optimistic about its
future earnings potential.

Despite the absence of a trailing P/E ratio and other valuation metrics like the
PEG ratio, price/book, and price/sales, Cardinal Health’s performance metrics underscore
impressive financial health. The company has achieved a robust revenue growth rate
of 22.40%, reinforcing its capability to expand operations and capture greater market
share. Furthermore, with an earnings per share (EPS) of 6.64, Cardinal Health demonstrates
solid earnings performance, albeit specifics on net income and return on equity 
remain undisclosed.

A significant highlight for investors is Cardinal Health’s strong free cash flow,
amounting to approximately $4.7 billion. Such financial fluidity not only strengthens
the company’s balance sheet but also supports its strategic investments and shareholder
returns, including dividends. With a dividend yield of 1.03% and a payout ratio 
of 30.66%, Cardinal Health presents an attractive proposition for income-focused
investors.

Analyst sentiment towards Cardinal Health paints a predominantly positive picture
with 12 buy ratings, 4 hold ratings, and just 1 sell rating. The average target 
price for the stock is $216.60, suggesting a potential upside of 9.29% from its 
current price. This potential increase could be enticing for investors looking for
growth opportunities within the healthcare sector.

Technical indicators further bolster Cardinal Health’s investment case. The stock’s
50-day moving average of $185.62 and 200-day moving average of $157.75 provide a
positive technical outlook, while a Relative Strength Index (RSI) of 75.88 indicates
that the stock is in overbought territory, warranting cautious optimism.

Cardinal Health operates through two main segments: Pharmaceutical and Specialty
Solutions, and Global Medical Products and Distribution. The company’s extensive
product line includes branded and generic pharmaceuticals, over-the-counter consumer
products, and a wide array of medical, surgical, and laboratory products. Moreover,
its services extend beyond distribution to include pharmacy management, radiopharmaceutical
manufacturing, and supply chain solutions, solidifying its role as a comprehensive
healthcare provider.

Incorporated in 1979, Cardinal Health has grown into a pivotal entity not just in
the United States but globally, underscoring its strategic importance in the healthcare
landscape. As it continues to enhance its service offerings and optimize operations
through technology, Cardinal Health remains a formidable player worth watching for
investors seeking steady growth and a reliable income stream in the healthcare sector.

Share on:
